A kolorektális rákok KRAS-mutációs státuszának hatása az Avastin-terápia hatékonyságára

Translated title of the contribution: Effect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer

Zita Hegedus, Tamás Barbai, Péter Tátrai, Balázs Hegedus, András Kiss, Erzsébet Rásó, György Bodoky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Anti-angiogenic therapy became a standard care of advanced colorectal cancer. Since the most frequent genetic alteration of colorectal cancer is KRAS mutation we have analyzed its effect on the efficacy of Avastin treatment. Since 2008 we have determined the KRAS status of 575 patients with colorectal carcinoma using a sensitive screening method and sequencing. In our database the frequency of KRAS mutation in colorectal cancer is 37% (codon 12: 31% followed by codon 13: 6%). We have examined the effect of KRAS status on the efficacy of Avastin treatment in 35 patients. Progression-free survival of KRAS mutant patients was highly similar to that of wild-type patients using log-rank test (9.2±5.5 months versus 8.7±5.7 months, respectively). Our data support those observations that KRAS status of colorectal cancer does not interfere with the efficacy of Avastin treatment.

Translated title of the contributionEffect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer
Original languageHungarian
Pages (from-to)99-104
Number of pages6
JournalMagyar onkologia
Volume55
Issue number2
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Effect of KRAS mutation status on the efficiency of Avastin therapy of colorectal cancer'. Together they form a unique fingerprint.

  • Cite this